Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: P2 receptor modulators - Inspire Pharmaceuticals

Drug Profile

Research programme: P2 receptor modulators - Inspire Pharmaceuticals

Alternative Names: INS 117284; INS 48506; INS 48821; INS 48824; Non-P2Y2 receptor modulators - Inspire; P2X3 receptor antagonists - Inspire; P2Y12 receptor antagonists - Inspire

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inspire Pharmaceuticals
  • Developer Inspire Pharmaceuticals; Merck & Co
  • Class
  • Mechanism of Action Purinergic P2 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Pain; Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Thrombosis in USA
  • 16 May 2011 Inspire Pharmaceuticals has been acquired by Merck & Co
  • 25 Mar 2009 Preclinical development is ongoing for Thrombosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top